Teduglutide Patent Expiration
Teduglutide is Used for treating adult patients with short bowel syndrome who depend on parenteral support. It was first introduced by Takeda Pharmaceuticals Usa Inc
Teduglutide Patents
Given below is the list of patents protecting Teduglutide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Gattex Kit |
US7847061 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity |
May 01, 2026
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US9060992 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity |
May 01, 2026
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US9539310 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity |
May 01, 2026
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US9545434 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity |
May 01, 2026
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US9545435 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity |
May 01, 2026
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US9555079 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity |
May 01, 2026
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US9572867 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity |
May 01, 2026
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US9592273 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity |
May 01, 2026
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US9592274 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity |
May 01, 2026
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US9968655 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity |
May 01, 2026
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US9968656 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity |
May 01, 2026
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US9968658 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity |
May 01, 2026
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US9974835 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity |
May 01, 2026
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US9974837 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity |
May 01, 2026
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US9981014 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity |
May 01, 2026
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US9981016 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity |
May 01, 2026
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US9987334 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity |
May 01, 2026
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US9987335 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity |
May 01, 2026
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US9993528 (Pediatric) | Treatment of short bowel syndrome patients with colon-in-continuity |
May 01, 2026
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US7847061 | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov 01, 2025
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US9060992 | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov 01, 2025
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US9539310 | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov 01, 2025
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US9545434 | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov 01, 2025
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US9545435 | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov 01, 2025
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US9555079 | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov 01, 2025
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US9572867 | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov 01, 2025
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US9592273 | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov 01, 2025
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US9592274 | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov 01, 2025
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US9968655 | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov 01, 2025
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US9968656 | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov 01, 2025
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US9968658 | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov 01, 2025
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US9974835 | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov 01, 2025
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US9974837 | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov 01, 2025
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US9981014 | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov 01, 2025
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US9981016 | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov 01, 2025
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US9987334 | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov 01, 2025
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US9987335 | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov 01, 2025
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US9993528 | Treatment of short bowel syndrome patients with colon-in-continuity |
Nov 01, 2025
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US7056886 (Pediatric) | GLP-2 formulations |
Mar 18, 2023
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US7056886 | GLP-2 formulations |
Sep 18, 2022
(Expired) | Takeda Pharms Usa |
| Gattex Kit |
US5789379 (Pediatric) | Glucagon-like peptide-2 analogs |
Oct 14, 2020
(Expired) | Takeda Pharms Usa |
| Gattex Kit | US5789379 | Glucagon-like peptide-2 analogs |
Apr 14, 2015
(Expired) | Takeda Pharms Usa |
Teduglutide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Teduglutide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | Takeda | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |